908 Devices Inc. Common Stock (MASS) Stock
Key stats
- Market cap
- $418.32M
- Price / Earnings ratio
- -11.9x
- EPS (TTM)
- -$0.94
- Volume
- Loading
- 52-week high
- $13.35
- 52-week low
- $5.03
Source: third-party data provider, as of November 13, 2026
Compare with MASS
Recent news

908 Devices to Report Third Quarter 2026 Financial Results on November 10, 2026
908 Devices to Report Third Quarter 2026 Financial Results on November 10, 2026
MASS

908 Devices to Present at the 32nd Annual Gabelli Aerospace & Defense Symposium
908 Devices to Present at the 32nd Annual Gabelli Aerospace & Defense Symposium
MASS

908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates
908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates
MASS

TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection
TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection
MASS
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 42.17
- MACD 12/26/9
- -0.29
- EMA 9 of MACD
- -0.10
- MACD histogram
- -0.19
- SMA 50
- $11.18
- Price below SMA 50
- EMA 50
- $10.98
- Price below EMA 50
- SMA 200
- $8.53
- Price above SMA 200
- EMA 200
- $8.80
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
No data available
Source: third-party data provider
Latest news

908 Devices to Report Third Quarter 2026 Financial Results on November 10, 2026
908 Devices to Report Third Quarter 2026 Financial Results on November 10, 2026
MASS

908 Devices to Present at the 32nd Annual Gabelli Aerospace & Defense Symposium
908 Devices to Present at the 32nd Annual Gabelli Aerospace & Defense Symposium
MASS

908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates
908 Devices Raises 2026 Outlook as Handheld Detection Demand Accelerates
MASS

TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection
TG Therapeutics Conference: 908 Devices Bets on Handheld Drug, Chemical Detection
MASS

908 Devices Eyes Growth in Handheld Drug and Chemical Detection Market
908 Devices Eyes Growth in Handheld Drug and Chemical Detection Market
MASS

908 Devices to Present at the 17th Annual Midwest IDEAS Investor Conference
908 Devices to Present at the 17th Annual Midwest IDEAS Investor Conference
MASS

908 Devices Q2 Earnings Call Highlights
908 Devices Q2 Earnings Call Highlights
MASS

908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates
908 Devices Inc. (MASS) Reports Q2 Loss, Tops Revenue Estimates
MASS

908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook
908 Devices Reports Second Quarter 2026 Financial Results and Raises Low End of 2026 Revenue Outlook
MASS

908 Devices Inc. (MASS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
908 Devices Inc. (MASS) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
MASS
News tone: automated (AI) classification of the article's content, not a price prediction.
About 908 Devices Inc. Common Stock
No description available.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Dr. Kevin J. Knopp Ph.D. | Co-Founder, CEO, President & Director | 1973 |
| Mr. Joseph H. Griffith IV | CFO & Treasurer | 1975 |
| Dr. Christopher David Brown Ph.D. | Co-Founder, Board Advisor & Director | 1975 |
| Mr. Mark S. Levine J.D. | Chief Legal, Administrative Officer & Corporate Secretary | 1973 |
| Mr. John Kenneweg | Senior Vice President of Sales and Product Marketing | 1973 |
| Ms. Julie Cincotti | Global Head of Human Resources | — |
| Dr. Kevin McCallion Ph.D. | Senior Vice President of Products and Production | 1966 |
| Mr. Kola Otitoju | Chief Business & Strategy Officer | 1973 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 42.17
- MACD 12/26/9
- -0.29
- EMA 9 of MACD
- -0.10
- MACD histogram
- -0.19
- SMA 50
- $11.18
- Price below SMA 50
- EMA 50
- $10.98
- Price below EMA 50
- SMA 200
- $8.53
- Price above SMA 200
- EMA 200
- $8.80
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
2 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $13.50
- Average
- $13.75
- High
- $14.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -22.2 | +7.8 | ||||||||||
| 2022 | -39.8 | +2.0 | +14.1 | -13.9 | -24.0 | +52.9 | +4.9 | -10.8 | -10.1 | -3.4 | -31.8 | -27.4 |
| 2023 | +27.0 | -4.6 | -2.6 | -20.7 | +40.0 | -21.6 | -0.1 | +8.6 | -6.3 | -6.9 | +29.0 | +45.7 |
| 2024 | -28.6 | +1.9 | +2.7 | -17.4 | +10.9 | -16.9 | +19.3 | -22.2 | -6.7 | -7.6 | -20.8 | -23.3 |
| 2025 | +14.2 | -2.2 | +126.3 | +33.4 | +6.0 | +19.8 | +1.1 | -2.6 | +47.5 | -11.2 | -19.9 | -14.5 |
| 2026 | +24.0 | +11.5 | -7.4 | +10.0 | +23.5 | +0.8 | -9.8 | +26.7 | +15.9 | -10.1 | -1.5 |



